Assembly Biosciences (NASDAQ:ASMB) Shares Cross Above 200-Day Moving Average of $12.58

Assembly Biosciences, Inc. (NASDAQ:ASMB) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $12.58 and traded as high as $14.75. Assembly Biosciences shares last traded at $14.60, with a volume of 6,769 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research report on Thursday, June 20th. StockNews.com upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Friday, May 10th.

Assembly Biosciences Price Performance

The business’s 50-day simple moving average is $14.37 and its 200-day simple moving average is $12.58.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.74) by $1.08. The business had revenue of $5.79 million during the quarter. As a group, equities research analysts expect that Assembly Biosciences, Inc. will post -12.65 EPS for the current fiscal year.

Insider Activity

In other Assembly Biosciences news, Director John G. Mchutchison sold 2,117 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $14.93, for a total transaction of $31,606.81. Following the transaction, the director now directly owns 19,104 shares of the company’s stock, valued at approximately $285,222.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 7,188 shares of company stock valued at $97,934. Company insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Assembly Biosciences

A hedge fund recently bought a new stake in Assembly Biosciences stock. Marquette Asset Management LLC acquired a new stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned about 0.08% of Assembly Biosciences as of its most recent filing with the SEC. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.